Solifenacin in the Practice of Treating a Hyper Reflector Neurogenic Bladder

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
Published: Oct 31, 2019
DOI: https://doi.org/10.30841/2307-5090.3.2019.185347
Keywords:
neurogenic hyperreflex bladder, solifenacin, selective m-anticholinergics,

##plugins.themes.bootstrap3.article.main##

В. В. Спиридоненко
State Institution «Institute of Urology of NAMS of Ukraine», Ukraine

Abstract

The article provides a literature review of etiopathogenesis, clinic, diagnosis and treatment of neurogenic hyperreflex urination disorders of various origins. Separately, modern data on the effectiveness of solifenacin in these clinical cases are presented.

##plugins.themes.bootstrap3.article.details##

How to Cite
Спиридоненко, В. В. (2019). Solifenacin in the Practice of Treating a Hyper Reflector Neurogenic Bladder. Health of Man, (3), 27–32. https://doi.org/10.30841/2307-5090.3.2019.185347
Issue
No. 3 (2019)
Section
For practicing physicians
Copyright (c) 2020 В. В. Спиридоненко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biography

В. В. Спиридоненко, State Institution «Institute of Urology of NAMS of Ukraine»

Volodymyr V. Spyrydonenko

References

Ginsberg D. (2013) The epidemiology and pathophysiology of neurogenic bladder // Am J Manag Care.;19 (10 Suppl):s191-6.

Вишневский Е.Л. (2005) Гиперактивный мочевой пузырь // Материалы пленума Российского общества урологов. – Тюмень; 322–351.

De Sousa A., Kapoor H., Jagtap J., Sen M. (2007) Prevalence and factors affecting enuresis amongst primary school children // Indian J Urol; 23: 4: 354—357.

Dorsher P.T., Mcintosh P.M. (2012) Neurogenic Bladder // Advances in Urology; 2012: 816274.

Hamid R, Averbeck MA, Chiang H, Garcia A, Al Mousa RT, Oh SJ, Patel A, Plata M, Del Popolo G. (2018) Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury // World J Urol. Oct;36(10):1517-1527.

Liao L. (2015) Evaluation and Management of Neurogenic Bladder: What Is New in China? Int J Mol Sci. Aug 10;16(8):18580-600.

Dias ALN, Araújo FF, Cristante AF, Marcon RM, Barros Filho TEP, Letaif OB. (2015) Epidemiology of cauda equina syndrome. What changed until // Rev Bras Ortop. 2017 Dec 6;53(1):107-112.

Морозов В.И. (2009) Сочетание дисфункции висцеральных органов у детей с нейрогенной дисфункцией мочевого пузыря // Педиатрия, 2007; 6: 35–40.

Пугачев А.Г. Детская урология. – М: ГЕОТАР-Медиа; 832.

Athanascopoulos A., Gyftopoulos K, Giannitsas K, Fisfis J. (2003) Combination treatment with an blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol; 169: 2253–2256.

Sanjay S. (2011) Dysfunctional voiding: A review of the terminology, presentation, evaluation and management in children and adults //Indian J Urol; 27: 4: 437–447.

Савченко Н.Е., Мохорт В.А. (1970) Нейрогенные расстройства мочеиспускания. – Мн.: Беларусь, 244 с.

Морозов В.И., Ахунзянов А.А., Тахаутдинов Ш.К., Байбиков Р.С. (2005) Лечение нейрогенной дисфункции мочевого пузыря у детей (уронефрологические и неврологические аспекты) // Журн неврол и психиат; 7: 58–62.

Астапенко А.В., Лихачев С.А., Забродец Г.В. (2002) Нейрогенный мочевой пузырь: патогенез, классификация, клиника, диагностика, лечение // Белорусский мед. журн.; 2: 4–6.

Kroll P, Zachwieja J. (2016) Complications of untreated and ineffectively treated neurogenic bladder dysfunctions in children: our own practical classification. Eur Rev Med Pharmacol Sci. Apr;20(7):1229-37.

Джавад-Заде М.Д., Державин А.М. (1989) Нейрогенные дисфункции мочевого пузыря. – М.: Медицина; 384 с.

Nevéus T, von Gontard A., Hoebeke P. et al. (2006) The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Report from the Standardisation Committee of the International Children’s Continence Society // J Urol; 176: 314–324.

Chase J., Austin P., Hoebeke P., McKennat P. (2010) The Management of Dysfunctional Voiding in Children: A Report From the Standardisation Committee of the International Children’s Continence Society // J Urol; 183: 1296–1302.

Stöhrer M., Castro-Diaz D., Chartier-Kastler E. et al. (2003) Guidelines on neurogenic lower urinary tract dysfunction // European Association of Urology

Лихачев С.А., Строцкий А.В., Забродец Г.В. (2010) Современные аспекты стандартизации терминологии при нейрогенных расстройствах мочеиспускания у больных с поражением спинного мозга //Медицинские новости. – №1. – С. 8–14.

Вишневский Е.Л., Лоран О.Б., Вишневский А.Е. (2001) Клиническая оценка расстройств мочеиспускания. – М.: ТЕРРА. – 96 с.

Дифференциальная диагностика нервных болезней: Руководство для врачей / Под ред. Г.А. Акимова и М.М. Одинака. – Спб.: Гиппократ, 2001. – 664 с.

Hampel C, Betz D, Burger M, Nowak C, Vogel M. (2017) Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects // Urol Int.;98(3):350-357.

Stothers L, Tsang B, Nigro M, Lazare D, Macnab A. (2016) An integrative review of standardized clinical evaluation tool utilization in anticholinergic drug trials for neurogenic lower urinary tract dysfunction. Spinal Cord. Dec;54(12):1114-1120.

Аль-Шукри С.Х., Кузьмин И.В., Лукина Е.Е. (2012) .Медикамнтозное лечение больных с нейрогенной активностью мочевого пузыря // Нефрология. –Т. 16, № 1. –С. 57–2.

Appell RA, Abrams P, Drutz HP, Van Kerrebroeck PE, Millard R, Wein A. (2001) Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol. Apr;19(2):141-7.

Abrams P., Wein A. J. (2000) Introduction: Overactive bladder and its treatmens // Urology.; Vol. 55 (Suppl 5A): 1-2.

Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A. (2002) The Standartisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Subcommitte of ICS // Neur Urodyn.; 21: 167-78.

Chapple CR, Cardozo L, Steers WD, Govier FE. (2006) Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract. Aug;60(8):959-66.

Chilman-Blair K, Bosch JL. (2004) Solifenacin: treatment of overactive bladder. Drugs Today (Barc). Apr;40(4):343-53

Nadeau G, Schröder A, Moore K, Genois L, Lamontagne P, Hamel M, Pellerin E, Bolduc S. (2014) Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study. Can Urol Assoc J. Mar;8(3-4):118-23.

Bolduc S, Moore K, Nadeau G, Lebel S, Lamontagne P, Hamel M. (2010) Prospective open label study of solifenacin for overactive bladder in children. J Urol. Oct;184(4 Suppl):1668-73.

Tijnagel MJ, Scheepe JR, Blok BF. (2017) Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin. BMC Urol. Apr 13;17(1):30.

Amarenco G, Sutory M, Zachoval R, Agarwal M, Del Popolo G, Tretter R, Compion G, De Ridder D. (2017) Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the doubleblind, randomized, active– and placebocontrolled SONIC urodynamic study. Neurourol Urodyn. Feb; 36 (2): 414-421.

Hampel C, Betz D, Burger M, Nowak C, Vogel M. (2017) Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects. Urol Int. 2017; 98 (3): 350-357.

Serels SR, Toglia MR, Forero-Schwanhaeuser S, He W. (2010) Impact of solifenacin on diary-recorded and patientreported urgency in patients with severe overactive bladder (OAB) symptoms. Curr Med Res Opin. Oct; 26 (10): 2277-85.

Pagoria D, O’Connor RC, Guralnick ML. (2011) Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep. Oct, 12 (5): 351-7.

Kay GG, Ebinger U. (2008) Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. Nov; 62 (11): 1792-800.

Newgreen D, Bosman B, Hollestein-Havelaar A, Dahler E, Besuyen R, Sawyer W, Bolduc S, Rittig S. (2017) Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial. Eur Urol. Mar; 71 (3): 483-490.

Haab F, Cardozo L, Chapple C, Ridder AM (2005) Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. Mar;47(3):376-84.

Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A. (2015) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. Mar;67(3):577-88.

Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stölzel M, Herholdt C, MacDiarmid S (2016) BESIDE study investigators. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. Jul; 70 (1):136-145.

Wada N, Okazaki S, Kobayashi S, Hashizume K, Kita M, Matsumoto S, Kakizaki H. (2015) Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation. Hinyokika Kiyo. Jan;61(1):7-11.

Rosario D.J., Cutinha P.E., Chapple C.R. (1996) The effects of single-dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability // Eur Urol.; 30: 240.